Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib plus carboplatin added to neoadjuvant chemotherapy for early triple-negative breast cancer
NL-OMON47540Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of veliparib in triple-negative breast cancer (TNBC) and breast cancer (3 arms), sponsored by AbbVie Inc. Primary endpoint: Pathological complete response. Started Nov 2015; status: active, not recruiting.
02
Drugs
veliparib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on NL-OMON47540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47540.